Morgan Stanley analyst Joseph Moore maintains Analog Devices (NASDAQ:ADI) with a Equal-Weight and raises the price target from $173 to $177.
IMUNON Announces First Patient Enrolled In Phase 1/2 Clinical Trial Of IMNN-001 In Combination With bevacizumab In Advanced Ovarian Cancer
The MRD trial will evaluate the effect of this treatment combination on minimal residual disease.LAWRENCEVILLE, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development
